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Cardiovascular disease has been well known 
as the most frequent cause of death in many 
countries all over the world.1 Acute myocardial 
infarction (AMI) is a sudden clinical coronary 
event that has high mortality and morbidity 
rate. The survivals of AMI will have left 
ventricle (LV) remodelling and decreased cardiac 
functions in the following years due to necrosis 
of cardiomyocites after AMI leading to chronic 
heart failure. However, revascularization therapy 
such as percutaneous coronary intervention (PCI) 
and medications cannot regenerate the necrotic 
cardiomyocites. Stem cell (SC) therapy as 
novel strategy in management of AMI has been 
developing so fast recently. Potential beneficial 
mechanism of SC therapy after AMI includes 
myocardial preservation, decreased infarct 
expansion and myocardial regeneration.2,3 To 
date, SC therapy in management of AMI seemed 
feasible and safe in clinical practice.4
Number of trials had been conducted to 
search for promising results and answers to many 
questions regarding the matter. The TOPCARE-
AMI (transplantation of progenitor cells and 
regeneration enhancement in acute myocardial 
infarction) with 59 patients showed improvement 
in ejection fraction and infarct size after 1 year 
follow-up.5 The REPAIR-AMI (reinfusion of 
enriched progenitor cells and infarct remodelling 
in acute myocardial infarction) trial with larger 
samples of 204 patients showed improvement 
in global LVEF at 4 months follow up from 
48.3%±9.2% to 53.8%±10.2%.6 A systematic 
review of SC therapy in AMI with 13 RCT and 
811 enrolled patients indicated LV function 
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improvement in short term follow-up.7
Percutaneus coronary intervention (PCI) 
as revascularization strategy in AMI is well-
established. However, there are always possible 
risks of post-complication such as sub-acute 
stent thrombosis, restenosis and vascular rupture 
resulting in complicated recurrent ischemic 
events. Predisposition of thrombus formation, 
which is postulated by Virchow, includes 
abnormalities of blood flow, blood constituent 
and vessel wall. Even one of those factors 
will predispose to “hypercoagulable state”.8 
Coagulation reaction induced by vascular injury 
in patients with AMI. Alteration in the kinetic 
of coagulant reactions suggest that systemic 
coagulation pathways in AMI is hypereactive 
or stimulated, resulting in thrombin formation 
and platelet activation.9 The clinical fact is that 
patients with recent AMI have an increased risk of 
recurrent coronary events. Activated coagulation 
associated with AMI might help explain 
the patophysiology of it. Persistent platelet 
hyperactivity has an important role in post-PCI 
thrombosis complication. PREPARE study had 
shown higher ADP-induced platelet aggregation 
in patients who had recurrent ischemic events 
after 6 months from AMI.10 During and after 
AMI, the mechanism of hemostatic changes 
remains unclear. Theoretically, hemostatic 
profiles will determine the “prothrombotic state” 
and ischemic events occurrence. One of the 
original article in this edition is a study by Irawan 
C et al.,11 investigated the hemostatic paramaeter 
changes of pre-post intracoronary injection of 
peripheral blood stem cell (PBCS) in patients 
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with recent AMI at baseline and 3 months after 
combined G-CSF and erythropoetin (EPO) based 
SC therapy.12 Hemostatic parameters measured 
were platelet aggregation, blood and plasma 
viscosity, Prothrombin time (PT), APTT, CRP 
and fibrinogen. Aim of this study was to observe 
the parameter changes in hemostasis profile 
before and after SC therapy in AMI. Baseline 
examination showed mixed result from below 
to above normal viscosity laboratory value 
range. The interesting result is that there was 
“normalization” of some hemostatic parameter 
in some patients after 3 months follow-up. 
More specific and larger studies should be done 
to explain the mechanism of these hemostatic 
parameter changes. The CRP and fibrinogen 
level, which are also known as inflammatory 
markers, showed decreasing level after 3 months. 
The relationship between activated coagulation 
pathway and systemic inflammatory activation in 
AMI is an important thing to explore in clinical 
studies.
Studies regarding SC therapy in AMI had 
various outcomes in term of cardiac parameter 
improvement. Actually there are many factors 
that influence the outcomes of SC therapy in 
AMI. One of them might be the influence of 
hemostatic status in AMI patients. Studies 
on hemostatic profile would be needed more 
to better understanding the mechanism of 
hemostatic changes in AMI patients treated with 
SC therapy. In the future, this field of research 
might attract attention to encourage novel 
strategy in AMI management with SC therapy.
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